健康元（600380）披露公司产品纳入国家医保目录，12月08日股价下跌0.79%

Core Viewpoint - Health元药业集团股份有限公司 has successfully had 218 products included in the new National Medical Insurance Directory, which is expected to positively impact the company's future operating performance, although it will not have a significant effect in the current period [1]. Group 1: Stock Performance - As of December 8, 2025, Health元's stock closed at 12.54 yuan, down 0.79% from the previous trading day, with a total market capitalization of 22.941 billion yuan [1]. - The stock opened at 12.63 yuan, reached a high of 12.76 yuan, and a low of 12.48 yuan, with a trading volume of 2.51 billion yuan and a turnover rate of 1.09% [1]. Group 2: Product Inclusion in National Medical Insurance Directory - On December 7, 2025, the National Medical Insurance Bureau released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, which includes 218 products from Health元 and its subsidiaries [1]. - Among the included products, 94 are classified as Category A and 124 as Category B [1]. - Notable inclusions are the injectable Aripiprazole microspheres and the injectable Triptorelin acetate microspheres, which now have an added indication for endometriosis [1]. - The renewal of the Tobramycin inhalation solution and injectable Esomeprazole sodium was also successful, with no products being removed from the directory [1]. - The new directory will take effect on January 1, 2026, and while it is expected to have a positive impact on future sales, the sales performance remains subject to policy and market uncertainties [1].